Focus on: ADT in the Modern Era- Balancing Cancer Control and Cardiovascular Safety Webcast (2026)
Availability
On-Demand
Expires on May 22, 2027
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credit Credits
1.5 Participation Credits

New for 2026, Focus on: are a series of accredited sessions offering an in-depth exploration of key clinical topics aligned with AUA’s ongoing needs assessments. This session will update the urologic care team on the latest advances in androgen deprivation therapy (ADT) treatment and the rapidly evolving management of advanced prostate cancer while providing a deeper dive into collaborating with a multidisciplinary team, implementing streamlined monitoring strategies, and shared decision making.

ACKNOWLEDGEMENTS
Independent educational grant support provided by:
  • Pfizer, Inc
  • Sumitomo Pharma America, Inc.
After participating in this CME activity, participants will be able to:
  1. Integrate cardiovascular (CV) risk assessment into ADT initiation by applying key findings from the REVELUTION-1 trial to identify patients at elevated risk for atherosclerosis and MACE.
  2. Compare and apply the CV safety profiles of LHRH agonists versus GnRH receptor antagonists to guide personalized ADT selection in patients with varying CV risk.
  3. Implement streamlined monitoring strategies for men on oral ADT, including testosterone levels, lipid and blood pressure evaluation, and surveillance for early CV risk indicators.
  4. Collaborate with cardiology and primary care to optimize statin use and coordinate CV risk-reduction strategies for prostate cancer patients receiving ADT.
  5. Strengthen shared decision making and adherence by incorporating discussions of oncologic benefit, CV risk, and mitigation strategies into routine oral ADT counseling and follow-up.
FACULTY DISCLOSURES
Name Company Name Relationship Type End Date
Joshua Levenson, MD No relevant relationships to disclose
Alicia Morgans, MD, MPH Bayer Consultant or Advisor Current
Astra Zeneca Consultant or Advisor Current
Astellas Consultant or Advisor Current
Dendreon Consultant or Advisor Current
Merck Consultant or Advisor Current
BMS Consultant or Advisor Current
Pfizer Consultant or Advisor Current
Advanced Accelerator Applications Consultant or Advisor Current
Lantheus Consultant or Advisor Current
Telix Consultant or Advisor Current
Novartis Consultant or Advisor Current
Macrogenics Consultant or Advisor Current
Curium Consultant or Advisor Current
Tolmar Consultant or Advisor Current
Eli Lilly Consultant or Advisor Current
LOXO@Lilly Consultant or Advisor Current
Sumitomo Pharma, Inc. Consultant or Advisor Current
GSK Consultant or Advisor Current
Exact Sciences Consultant or Advisor Current
Johnson and Johnson Consultant or Advisor Current
Sanoj Punnen. MD Telix Consultant or Advisor Current
Preston C. Sprenkle, MD Telix Pharmaceuticals Consultant or Advisor Current
Profound Medical Consultant or Advisor Current
Angiodynamic Inc Consultant or Advisor Current
Insight Medbotics Consultant or Advisor Current

EDUCATION COUNCIL DISCLOSURES

Education Council 2025

COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group 2025


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2026
Expiration Date: May, 2027

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.



AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.